Literature DB >> 2850301

Enzyme linked immunosorbent assay (ELISA) for cytomegalovirus antibody in donor plasma.

S Ramskill1, P Senior, P Barlow, L A Tovey.   

Abstract

An adaptation of an enzyme immunoassay technique was developed to screen donor plasma for high titres of antibodies to cytomegalovirus (CMV). The technique uses microtitre plates treated with glutaraldehyde and coated with CMV antigen and an anti-IgG alkaline phosphatase conjugate to detect the captured antibody. Using an anti-CMV standard with a 1/64 titre by complement fixation, 34 (6.8%) of 500 sera were shown to have an antibody titre that was acceptable to the Blood Products Laboratory in England for anti-CMV immunoglobulin production.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2850301      PMCID: PMC1141737          DOI: 10.1136/jcp.41.11.1233

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  5 in total

1.  Enzyme immunoassays in diagnostic medicine. Theory and practice.

Authors:  A Voller; D E Bidwell; A Bartlett
Journal:  Bull World Health Organ       Date:  1976       Impact factor: 9.408

2.  Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients.

Authors:  R M Condie; R J O'Reilly
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

3.  Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation.

Authors:  J D Meyers; J Leszczynski; J A Zaia; N Flournoy; B Newton; D R Snydman; G G Wright; M J Levin; E D Thomas
Journal:  Ann Intern Med       Date:  1983-04       Impact factor: 25.391

4.  Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation.

Authors:  R A Bowden; M Sayers; N Flournoy; B Newton; M Banaji; E D Thomas; J D Meyers
Journal:  N Engl J Med       Date:  1986-04-17       Impact factor: 91.245

5.  Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. Preliminary results of a controlled trial.

Authors:  D J Winston; W G Ho; C H Lin; M D Budinger; R E Champlin; R P Gale
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.